Cellectis Announces Appointments of Axel-Sven Malkomes and Donald A Bergstrom, MD, Ph.D. to its Board of Directors


NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company, which is using its pioneering TALEN® genome-editing technology to develop potential innovative therapies for treatment of serious illnesses, announced today that at its Combined General Meeting, Axel-Sven Malkomes and Donald A. Bergstrom, MD, Ph.D., were appointed directors of the Company’s Board of Directors, with immediate effect.

“We are pleased to continue our work with Dr. Bergstrom and to welcome Mr. Malkomes to the Cellectis Board of Directors. Both are seasoned leaders with decades of experience in the healthcare industry. and financial services. We are confident that they will add valuable value as we continue our development to become an end-to-end cell and gene therapy company,” said Dr. André Choulika, Chief Executive Officer of Cellectis.

Donald A Bergstrom, MD, Ph.D.

Effective immediately, Dr. Bergstrom will be a member of the Cellectis Board of Directors. Donald A Bergstrom, MD, Ph.D., had been appointed non-voting member of the Company’s Board of Directors on November 4, 2021.

Dr. Bergstrom, currently serves as Executive Vice President, Head of Research and Development at Relay Therapeutics, Inc., a clinical-stage precision medicine company. He has over 15 years of experience in the biopharmaceutical and medical industries.

Prior to joining Relay Therapeutics Inc, Dr. Bergstrom was Medical Director at Mersana Therapeutics, where he worked on two products based on Mersana’s proprietary antibody-drug conjugate platform through non-clinical development and in Phase 1 clinical trials. 1. He was also Global Head of Translational and Experimental Medicine at Sanofi Oncology. Before joining Sanofi, he held positions of responsibility in Merck research laboratories, such as manager of the oncology and experimental medicine franchise. Dr. Bergstrom holds a medical degree (MD) from the University of Washington in Seattle, where he was also a resident in clinical pathology, and a doctorate (Ph.D.) from the Fred Hutchinson Cancer Research Center , where he completed post-doctoral training.

Axel-Sven Malkomes

Until March 31, 2022, Axel-Sven Malkomes was Chief Financial Officer and Chief Commercial Officer of Medigene AG, a clinical-stage immuno-oncology company developing T-cell based immunotherapies for the treatment of cancer. Axel-Sven has over 25 years of experience in the healthcare industry.

Prior to joining Medigene, Mr. Malkomes was Vice President and Head of Life Sciences at UK bank Barclays in Europe. Prior to joining Barclays, he was Global Head of Healthcare and Chemicals Investment Banking at Société Générale.

On the investment side, Mr. Malkomes worked for several years at UK listed private equity firm, 3i plc, as co-head of healthcare investments in Europe. Previously, he held senior operational roles at German pharmaceutical company Merck KGaA, including as Director of Strategic Planning and Director of Mergers & Acquisitions/Business Development, where he was significantly involved in the establishment and development of the company’s oncology activity.

During his international career, Mr. Malkomes has acquired in-depth knowledge of the pharmaceutical industry.

About Cellectis
Cellectis is a clinical-stage biotechnology company, which uses its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis is developing the first allogeneic immunotherapies therapeutic products based on CAR-T cells, inventing the concept of engineered off-the-shelf, ready-to-use CAR-T cells for the treatment of cancer patients, and a platform to realize therapeutic genetic modifications in hematopoietic stem cells in various diseases. By capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and the pioneering PulseAgile electroporation technology, Cellectis is developing innovative product candidates using the power of the immune system to treat it. illnesses with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis aims to develop UCART product candidates directed to the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, leukemia Acute B-cell lymphoblastic and multiple myeloma. .HEAL is a new platform focused on hematopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases. Cellectis’ head office is located in Paris. Cellectis is also established in New York and Raleigh in the United States.

Cellectis is listed on the Euronext Growth market (code: ALCLS)
as well as on the Nasdaq Global Market (code: CLLS).

For more information, visit our website: www.cellectis.com
Follow Cellectis on social networks: @cellectis, LinkedIn and YouTube.

TALEN® is a registered trademark owned by Cellectis.
For more information, please contact:

Media contacts:
Pascalyne Wilson, Director, communications, 07 76 99 14 33,
[email protected]

Investor relations contact:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, [email protected] Sandya von der Weid, Associate Director, LifeSci Advisors, +41786800538

Warning
This press release contains forward-looking statements about the Company’s objectives, which are based on our current estimates and assumptions and on information currently available to us, including information provided or made public by our licensees. Forward-looking statements are subject to known and unknown risks, uncertainties, including the many risks associated with the development of biopharmaceutical product candidates. Further information on the risk factors that may affect the company’s business and its financial performance are set out in Cellectis’ annual report in English entitled “Form 20-F” for the financial year ended December 31, 2021, in the financial report (including the management report of the board of directors) for the financial year ended December 31, 2021 and the documents subsequently filed by Cellectis with the Securities Exchange Commission. Except as required by applicable law, we disclaim any obligation to update and release these forward-looking statements, or to update why actual results may differ materially from those anticipated in the forward-looking statements, even if new information was available in the future.

  • Appointments_AG_PR_English.pdf



Source link -88